Oral proteasome inhibitor with strong preclinical efficacy in myeloma models
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Oral proteasome inhibitor with strong preclinical efficacy in myeloma models ; volume:16 ; number:1 ; day:24 ; month:3 ; year:2016 ; pages:1-10 ; date:12.2016
BMC cancer ; 16, Heft 1 (24.3.2016), 1-10, 12.2016
- Urheber
-
Park, Jonghoon
- Beteiligte Personen und Organisationen
-
Park, Eok
Jung, Cheol-Kyu
Kang, Seung-Wan
Kim, Byung Gyu
Jung, Youngjoo
Kim, Tae Hun
Lim, Ji-Young
Lee, Sung-Eun
Min, Chang-Ki
Won, Kwang-Ai
SpringerLink (Online service)
- DOI
-
10.1186/s12885-016-2285-2
- URN
-
urn:nbn:de:1111-2016033012880
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Park, Jonghoon
- Park, Eok
- Jung, Cheol-Kyu
- Kang, Seung-Wan
- Kim, Byung Gyu
- Jung, Youngjoo
- Kim, Tae Hun
- Lim, Ji-Young
- Lee, Sung-Eun
- Min, Chang-Ki
- Won, Kwang-Ai
- SpringerLink (Online service)
Ähnliche Objekte (12)
Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma
Proteasome inhibition: the dawn of novel therapies in multiple myeloma
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma
Tetrahydrobiopterin induces proteasome inhibitor resistance and tumor progression in multiple myeloma
MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma
Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses
Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma
Mechanisms of preferential bone formation in myeloma bone lesions by proteasome inhibitors
Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor
The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma
Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies
Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma
Proteasome inhibition: the dawn of novel therapies in multiple myeloma
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma
Tetrahydrobiopterin induces proteasome inhibitor resistance and tumor progression in multiple myeloma
MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma
Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses
Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma
Mechanisms of preferential bone formation in myeloma bone lesions by proteasome inhibitors
Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor
The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma
Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies
Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma
Proteasome inhibition: the dawn of novel therapies in multiple myeloma
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma
Tetrahydrobiopterin induces proteasome inhibitor resistance and tumor progression in multiple myeloma
MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma
Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses
Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma
Mechanisms of preferential bone formation in myeloma bone lesions by proteasome inhibitors
Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor
The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma